HLB Liver Cancer Drug Approval Review (HLB 간암 신약 허가 심사)Compare →
Last 30 days: first seen Nov 4 · 0.2h on the board · best rank #8
- Daum 100%
Picked up by Daum only — may be platform-internal dynamics.
Sample — 1 cross-checked sources · 2 snapshots (5-min interval)
Not on the board right now — here's the record of when it was.
«HLB 간암 신약 허가 심사» first surfaced on November 4, 2026, held the board for 0.2h over the last 30 days, peaking at #8. The driver: “New HLB Liver Cancer Drug Makes Re-attempt for US FDA Approval… Decision Expected Next April”. Currently off the board.
Why it's trending
New HLB Liver Cancer Drug Makes Re-attempt for US FDA Approval… Decision Expected Next April— 비즈워치
This is an actual headline, quoted as-is — never summarized or generated.
Related video
HLB 간암 신약 허가 심사
HLB, 간암 신약 FDA 문턱서 좌절…효능·안전성 문제 아니다
A YouTube video found by searching this keyword.
Related coverage
- HLB 간암 신약, 美 FDA 허가 재도전…내년 4월 결론 — 비즈워치
- HLB 간암 신약, FDA 본심사 재개…내년 4월 9일 허가 판가름 — 히트뉴스
- HLB 간암 신약, FDA 'Class 2'로 분류…내년 4월 허가 심사 결론 — MTN 머니투데이방송
- HLB 간암 신약 FDA 본심사 재개…내년 4월 허가 여부 결정 By EBN — Investing.com 한국어
·
HLB 간암 신약 허가 심사 first appeared on KoreaTrendBoard on November 4, 2026. It has been observed 2 times since, peaking at rank 8 with a score of 25.0. It was last seen on November 4, 2026.
Loading
This chart shows the last 14 days. Pro opens 180 days and lets you export the same data as CSV — one row per day with rank, score and source count. See what opens →
The full board on 2026-11-04 → · This week · Glossary
Picked up by: DaumReferenced from each site's publicly available rankings. No affiliation or partnership.
Want a heads-up when «HLB 간암 신약 허가 심사» climbs again? It's free.
No signup form — your email is the account. One click to stop.
- 180-day history — the curve, not the moment
- Alerts — pinged within 5 minutes when your keyword moves
- API — ranks and scores straight into your report